Key Informant Views on Potential Acceptability and Feasibility of Long-acting Antiretroviral Treatment for HIV in Kenya

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2024 Apr 19

PMID 38641565

Authors

Anne Kaggiah

Catherine N Maina

John Kinuthia

Douglas Barthold

Brett Hauber

Jacinda Tran

Jane M Simoni

Susan M Graham

Affiliations

Soon will be listed here.

Abstract

Background: In 2020, 14% of diagnosed persons living with HIV (PLWH) in Kenya were not taking antiretroviral therapy (ART), and 19% of those on ART had unsuppressed viral loads. Long-acting antiretroviral therapy (LA-ART) may increase viral suppression by promoting ART uptake and adherence. We conducted key informant (KI) interviews with HIV experts in Kenya to identify product and delivery attributes related to the acceptability and feasibility of providing LA-ART to PLWH in Kenya.

Methods: Interviews were conducted via Zoom on potential LA-ART options including intra-muscular (IM) injections, subcutaneous (SC) injections, implants, and LA oral pills. KI were asked to discuss the products they were most and least excited about, as well as barriers and facilitators to LA-ART roll-out. In addition, they were asked about potential delivery locations for LA-ART products such as homes, pharmacies, and clinics. Interviews were recorded and transcribed, and data were analyzed using a combination of inductive and deductive coding.

Results: Twelve KI (5 women, 7 men) participated between December 2021 and February 2022. Overall, participants reported that LA-ART would be acceptable and preferable to PLWH because of fatigue with daily oral pills. They viewed IM injections and LA oral pills as the most exciting options to ease pill burden and improve adherence. KI felt that populations who could benefit most were adolescents in boarding schools and stigmatized populations such as sex workers. SC injections and implants were less favored, as they would require new training initiatives for patients or healthcare workers on administration. In addition, SC injections would require refrigeration and needle disposal after use. Some KI thought patients, especially men, might worry that IM injections and implants would impact fertility, given their role in family planning. Pharmacies were perceived by most KI as suboptimal delivery locations; however, given ongoing work in Kenya to include pharmacies in antiretroviral delivery, they recommended asking patients their views.

Conclusion: There is interest and support for LA-ART in Kenya, especially IM injections and LA oral pills. Identifying patient preferences for modes and delivery locations and addressing misconceptions about specific products as they become available will be important before wide-scale implementation.

References

Flexner C, Owen A, Siccardi M, Swindells S . Long-acting drugs and formulations for the treatment and prevention of HIV infection. Int J Antimicrob Agents. 2020; 57(1):106220. PMC: 7790856. DOI: 10.1016/j.ijantimicag.2020.106220. View

Nachega J, Scarsi K, Gandhi M, Scott R, Mofenson L, Archary M . Long-acting antiretrovirals and HIV treatment adherence. Lancet HIV. 2023; 10(5):e332-e342. PMC: 10734401. DOI: 10.1016/S2352-3018(23)00051-6. View

Graham S, Barthold D, Hauber B, Brah A, Saldarriaga E, Collier A . U.S. patient preferences for long-acting HIV treatment: a discrete choice experiment. J Int AIDS Soc. 2023; 26 Suppl 2:e26099. PMC: 10338996. DOI: 10.1002/jia2.26099. View

Kityo C, Cortes C, Phanuphak N, Grinsztejn B, Venter F . Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of HIV in Low- and Middle-Income Countries (LMICs). Clin Infect Dis. 2022; 75(Suppl 4):S549-S556. DOI: 10.1093/cid/ciac752. View

Brah A, Barthold D, Hauber B, Collier A, Ho R, Marconi V . The systematic development of attributes and levels for a discrete choice experiment of HIV patient preferences for long-acting antiretroviral therapies in the United States. AIDS Res Ther. 2022; 19(1):13. PMC: 8881811. DOI: 10.1186/s12981-022-00435-6. View

Godman B, Basu D, Pillay Y, Almeida P, Mwita J, Rwegerera G . Ongoing and planned activities to improve the management of patients with Type 1 diabetes across Africa; implications for the future. Hosp Pract (1995). 2020; 48(2):51-67. DOI: 10.1080/21548331.2020.1745509. View

Havlir D, Gandhi M . Implementation challenges for long-acting antivirals as treatment. Curr Opin HIV AIDS. 2015; 10(4):282-9. PMC: 5847341. DOI: 10.1097/COH.0000000000000158. View

Toska E, Zhou S, Chen-Charles J, Gittings L, Operario D, Cluver L . Factors Associated with Preferences for Long-Acting Injectable Antiretroviral Therapy Among Adolescents and Young People Living with HIV in South Africa. AIDS Behav. 2023; 27(7):2163-2175. PMC: 9827015. DOI: 10.1007/s10461-022-03949-2. View

Abu Hassan H, Tohid H, Amin R, Bidin M, Muthupalaniappen L, Omar K . Factors influencing insulin acceptance among type 2 diabetes mellitus patients in a primary care clinic: a qualitative exploration. BMC Fam Pract. 2013; 14:164. PMC: 4231611. DOI: 10.1186/1471-2296-14-164. View

10.

Jacobstein R . Liftoff: The Blossoming of Contraceptive Implant Use in Africa. Glob Health Sci Pract. 2018; 6(1):17-39. PMC: 5878070. DOI: 10.9745/GHSP-D-17-00396. View

11.

Menendez-Arias L, Delgado R . Update and latest advances in antiretroviral therapy. Trends Pharmacol Sci. 2021; 43(1):16-29. DOI: 10.1016/j.tips.2021.10.004. View

12.

Mutasa-Apollo T, Ford N, Wiens M, Socias M, Negussie E, Wu P . Effect of frequency of clinic visits and medication pick-up on antiretroviral treatment outcomes: a systematic literature review and meta-analysis. J Int AIDS Soc. 2017; 20(Suppl 4):21647. PMC: 6192466. DOI: 10.7448/IAS.20.5.21647. View

13.

Burke H, Packer C, Zingani A, Moses P, Bernholc A, Ruderman L . Testing a counseling message for increasing uptake of self-injectable contraception in southern Malawi: A mixed-methods, clustered randomized controlled study. PLoS One. 2022; 17(10):e0275986. PMC: 9578616. DOI: 10.1371/journal.pone.0275986. View

14.

Barthold D, Brah A, Graham S, Simoni J, Hauber B . Improvements to Survey Design from Pilot Testing a Discrete-Choice Experiment of the Preferences of Persons Living with HIV for Long-Acting Antiretroviral Therapies. Patient. 2022; 15(5):513-520. PMC: 9123156. DOI: 10.1007/s40271-022-00581-z. View

15.

Kibirige D, Olum R, Kyazze A, Bongomin F, Sanya R . Availability and affordability of essential medicines and diagnostic tests for diabetes mellitus in Africa. Trop Med Int Health. 2022; 27(11):942-960. DOI: 10.1111/tmi.13819. View

16.

Malterud K, Siersma V, Guassora A . Sample Size in Qualitative Interview Studies: Guided by Information Power. Qual Health Res. 2015; 26(13):1753-1760. DOI: 10.1177/1049732315617444. View

17.

Barthold D, Saldarriaga E, Brah A, Hauber B, Banerjee P, Fuller S . Preference for daily oral pills over long-acting antiretroviral therapy options among people with HIV. AIDS. 2023; 37(10):1545-1553. PMC: 10355802. DOI: 10.1097/QAD.0000000000003620. View

18.

Simoni J, Beima-Sofie K, Wanje G, Mohamed Z, Tapia K, McClelland R . "Lighten This Burden of Ours": Acceptability and Preferences Regarding Injectable Antiretroviral Treatment Among Adults and Youth Living With HIV in Coastal Kenya. J Int Assoc Provid AIDS Care. 2021; 20:23259582211000517. PMC: 7952847. DOI: 10.1177/23259582211000517. View

19.

Kerrigan D, Karver T, Muraleetharan O, Savage V, Mbwambo J, Donastorg Y . "A dream come true": Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania. PLoS One. 2020; 15(6):e0234666. PMC: 7292359. DOI: 10.1371/journal.pone.0234666. View

20.

Mantsios A, Murray M, Karver T, Davis W, Galai N, Kumar P . Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials. BMC Health Serv Res. 2021; 21(1):255. PMC: 7980753. DOI: 10.1186/s12913-021-06214-9. View